Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Recently, I had the honor of interviewing Dr Ross Macdonald, CEO of Cynata Therapeutics. In this interview, we discuss Cynata’s technology platform, the company’s world first achievements, and its clinical trial underway for GvHD. We also explore the company’s strategic goals and the importance of its partnership with Fujifilm in Japan. [Read more…]
In addition to cell therapy contract development and manufacturing organizations (CDMOs), there are numerous companies that offer CDMO services for other types of biologics. Biologics are defined as human, animal, or microorganism derived products used for therapeutic purposes. In addition to cell therapies, biologics can include vaccines, blood and blood products, human cells and tissues used for transplantation, and gene therapies.
While the services provided by these companies are not cell therapy CMDO services, these companies should be monitored, because their manufacturing capabilities and experience with biologics may position them expand into cell therapy CDMO services in the future. [Read more…]
In addition to commercial cell therapy CDMOs, there are other industry players that support the cell therapy industry, including academic and medical CDMOs. While these groups do contribute to the cell therapy CDMO market, their manufacturing capabilities are limited in scale and best suited to small, early-stage clinical trials. [Read more…]
Traditionally, the contract development and manufacturing organization (CDMO) market was for pharmaceutical services, including drug compound development and manufacturing. Over time, many pharmaceutical companies expanded into offering services for biopharmaceuticals and biologics as well, and a companies went as far as to specialize in cell therapy CDMO services. [Read more…]
A contract development and manufacturing organization (CDMO), is a company that serves cell therapy companies on a contract basis. Common cell therapy CDMO services include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
CDMOs allows cell therapy companies to outsource aspects of their business, which can support:
- Speed to market
- Adding technical expertise without overhead costs
- Cost efficiencies